Biological Markers for Identifying Ibrutinib Resistance in Patients Having Mantle Cell Lymphoma and Methods of Using the Same

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell lymphoma.